- Piramal and NP2 are set to complete the drug development phase of the generic cancer drug cyclophosphamide this October.
- The development and manufacturing activities are being conducted at Piramal’s dedicated sterile injectable facility in Lexington, Kentucky.
- This partnership addresses ongoing cyclophosphamide shortages and supply chain risks, safeguarding access to this critical medicine for patients across the U.S.
MUMBAI, India, Sept. 30, 2026 /PRNewswire/ — Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA) (BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October.
Cyclophosphamide, a widely prescribed generic, sterile injectable oncology medicine, is used to treat several cancers, including breast cancer and retinoblastoma, an eye cancer that occurs in young children.
“Advancing to the manufacturing stage is an exciting next step in NP2’s mission to manufacture a steady supply of the life-saving cancer-fighting medicine cyclophosphamide right here in the United States,” said Telly Athanasopoulos, NP2’s Head of Manufacturing. “Today’s announcement is good news for cancer patients and their doctors, who need a safe, reliable supply of cyclophosphamide at stable prices.”
According to a National Comprehensive Cancer Network (NCCN) survey conducted in late August of NCCN member institutions, 100% of respondents are experiencing a shortage of at least one anti-cancer agent and more than 20% of centers are currently in a shortage for five or more cancer medications. One such medicine is cyclophosphamide, which is currently in short supply in the EU and Canada. The top two cyclophosphamide manufacturers, both overseas, account for 92% of U.S. sales, and one currently serves nearly 70% of the U.S. 200 mg ready-to-use solution market., according to Q2 IQVIA sales data.
To combat this issue, NP2 has been conducting cyclophosphamide drug development at PPS’ Lexington site, where it will also manufacture cyclophosphamide, shortening and simplifying the supply chain between the manufacturing plant and cancer patients in the U.S. The Lexington site is currently undergoing an $85 million expansion to increase manufacturing capacity for drugs like cyclophosphamide.
“We are proud to partner with NP2 on this important initiative to strengthen the supply of critical oncology medicines for patients in the United States,” said Peter DeYoung, CEO of Piramal Global Pharma. “With the ongoing expansion of our Lexington facility, we are building a more resilient domestic supply chain and helping to support reliable access to this essential cancer therapy.”
“What we’re seeing with the cyclophosphamide shortages in the EU and Canada is clearly alarming,” said Terri Miller, Executive Director of NP2. “NP2 is committed to manufacturing a steady supply of cyclophosphamide, a life-saving cancer-fighting medicine, in the United States so it’s readily available to patients who need it to battle diseases like lymphoma and leukemia during one of the toughest times of their lives,” said Terri Miller, NP2’s Executive Director.
“The problem NP2 is committed to solve for patients isn’t about the science, it’s about the system,” Miller added. “Consolidation of cancer medicines’ manufacturing capacity overseas keeps cancer patients and their doctors up at night. A reliable U.S.-made supply of cyclophosphamide—a mainstay cancer-fighting medicine—does not exist today. NP2 is building it. We believe patients should be able to focus on fighting their cancer, not fretting about the availability of a life-saving drug they urgently need. That’s what motivates us to move forward,” Miller concluded.
This milestone in the PPS-NP2 partnership brings us closer to a future where patients in the U.S. have secure and reliable access to essential cancer medicines, regardless of geopolitical challenges or global supply chain disruptions.
About Piramal Pharma Solutions
Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited’s subsidiary, Yapan Bio Private Limited.
For more information visit: Piramal Pharma Solutions | LinkedIn | Facebook | X
About Piramal Pharma Limited
Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL’s associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market.
For more information, visit: Piramal Pharma | LinkedIn
About NP2
NP2 is a non-profit generic drug manufacturer building a more reliable, affordable, and resilient supply of life-saving medicines starting with mainstay oncology drugs. Its first medicine, a ready-to-use sterile injectable form of cyclophosphamide, is being developed for manufacture in Lexington, Kentucky and is expected to reach market in mid-2028. www.np2.org
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/piramal-pharma-solutions-and-np2-to-complete-cyclophosphamide-development-phase-next-month-302894516.html
